The NF-κB subunit c-Rel regulates Bach2 tumour suppressor expression in B-cell lymphoma

Oncogene

Volumn 35, Issue 26, 2016, Pages 3476-3484

  Hunter, J E ^a   Butterworth, J A ^a   Zhao, B ^b   Sellier, H ^a   Campbell, K J ^c   Thomas, H D ^a   Bacon, C M ^a   Cockell, S J ^a   Gewurz, B E ^b   Perkins, N D ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACH2 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MYC PROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR REL; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; BACH2 PROTEIN, MOUSE; BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; ONCOPROTEIN; RELA PROTEIN, MOUSE; TCL1 PROTEIN, MOUSE; TRANSCRIPTION FACTOR RELA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPHOMA CELL; LYMPHOMAGENESIS; MOUSE; NONHUMAN; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEPLETION; WESTERN BLOTTING; ANIMAL; DEFICIENCY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE;

ANIMALS; APOPTOSIS; B-LYMPHOCYTES; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; BLOTTING, WESTERN; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, B-CELL; MICE, KNOCKOUT; MICE, TRANSGENIC; NF-KAPPA B; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; PROTO-ONCOGENE PROTEINS C-REL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTOR RELA; TUMOR SUPPRESSOR PROTEINS;

EID: 84976870688     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.399     Document Type: Article

References (53)

1. Perkins ND. The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer 2012; 12: 121-132.
2. Staudt LM. Oncogenic activation of NF-κB. Cold Spring Harb Perspect Biol 2010; 2: a000109.
3. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001; 194: 1861-1874.
4. Feuerhake F, Kutok JL, Monti S, Chen W, LaCasce AS, Cattoretti G et al. NFκB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 2005; 106: 1392-1399.
5. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198: 851-862.
6. Kuppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009; 9: 15-27.
7. Perkins ND. Integrating cell-signalling pathways with NF-κB and IKK function. Nat Rev Mol Cell Biol 2007; 8: 49-62.
8. Gilmore TD. Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel. Oncogene 1999; 18: 6925-6937.
9. Fullard N, Wilson CL, Oakley F. Roles of c-Rel signalling in inflammation and disease. Int J Biochem Cell Biol 2012; 44: 851-860.
10. Courtois G, Gilmore TD. Mutations in the NF-κB signaling pathway: implications for human disease. Oncogene 2006; 25: 6831-6843.
11. Grumont RJ, Gerondakis S. The subunit composition of NF-κB complexes changes during B-cell development. Cell Growth Differ 1994; 5: 1321-1331.
12. Liou HC, Sha WC, Scott ML, Baltimore D. Sequential induction of NF-κB/Rel family proteins during B-cell terminal differentiation. Mol Cell Biol 1994; 14: 5349-5359.
13. Weih F, Carrasco D, Bravo R. Constitutive and inducible Rel/NF-κB activities in mouse thymus and spleen. Oncogene 1994; 9: 3289-3297.
14. Kontgen F, Grumont RJ, Strasser A, Metcalf D, Li R, Tarlinton D et al. Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev 1995; 9: 1965-1977.
15. Tumang JR, Hsia CY, Tian W, Bromberg JF, Liou HC. IL-6 rescues the hyporesponsiveness of c-Rel deficient B cells independent of Bcl-xL, Mcl-1, and Bcl-2. Cell Immunol 2002; 217: 47-57.
16. Tumang JR, OwyangA, Andjelic S, Jin Z,Hardy RR, LiouML et al. c-Rel is essential for B lymphocyte survival and cell cycle progression. Eur J Immunol 1998; 28: 4299-4312.
17. Cariappa A, Liou HC, Horwitz BH, Pillai S. Nuclear Factor κB is required for the development of marginal zone B lymphocytes. J Exp Med 2000; 192: 1175-1182.
18. Starczynowski DT, Reynolds JG, Gilmore TD. Deletion of either C-terminal transactivation subdomain enhances the in vitro transforming activity of human transcription factor REL in chicken spleen cells. Oncogene 2003; 22: 6928-6936.
19. Chin M, Herscovitch M, Zhang N, Waxman DJ, Gilmore TD. Overexpression of an activated REL mutant enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profile. Oncogene 2009; 28: 2100-2111.
20. Fan Y, Rayet B, Gelinas C. Divergent C-terminal transactivation domains of Rel/NF-κB proteins are critical determinants of their oncogenic potential in lymphocytes. Oncogene 2004; 23: 1030-1042.
21. Barth TF, Martin-Subero JI, Joos S, Menz CK, Hasel C, Mechtersheimer G et al. Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma. Blood 2003; 101: 3681-3686.
22. Joos S, Menz CK, Wrobel G, Siebert R, Gesk S, Ohl S et al. Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2. Blood 2002; 99: 1381-1387.
23. Martin-Subero JI, Gesk S, Harder L, Sonoki T, Tucker PW, Schlegelberger B et al. Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood 2002; 99: 1474-1477.
24. Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008; 319: 1676-1679.
25. Enciso-Mora V, Broderick P, Ma Y, Jarrett RF, Hjalgrim H, Hemminki K et al. A genomewide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). Nat Genet 2010; 42: 1126-1130.
26. Curry CV, Ewton AA, Olsen RJ, Logan BR, Preti HA, Liu YC et al. Prognostic impact of C-REL expression in diffuse large B-cell lymphoma. J Hematop 2009; 2: 20-26.
27. Chien Y, Scuoppo C, Wang X, Fang X, Balgley B, Bolden JE et al. Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity. Genes Dev 2011; 25: 2125-2136.
28. Jing H, Kase J, Dorr JR, Milanovic M, Lenze D, Grau M et al. Opposing roles of NF-κB in anti-cancer treatment outcome unveiled by cross-species investigations. Genes Dev 2011; 25: 2137-2146.
29. Keller U, Huber J, Nilsson JA, Fallahi M, Hall MA, Peschel C et al. Myc suppression of Nfkb2 accelerates lymphomagenesis. BMC cancer 2010; 10: 348.
30. Keller U, Nilsson JA, Maclean KH, Old JB, Cleveland JL. Nfkb 1 is dispensable for Myc-induced lymphomagenesis. Oncogene 2005; 24: 6231-6240.
31. Carlsen H, Moskaug JO, Fromm SH, Blomhoff R. In vivo imaging of NF-κB activity. J Immunol 2002; 168: 1441-1446.
32. Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, Adams JM. The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med 1988; 167: 353-371.
33. Hoyer KK, French SW, Turner DE, Nguyen MT, Renard M, Malone CS et al. Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma. Proc Natl Acad Sci USA 2002; 99: 14392-14397.
34. Fan Y, Dutta J, Gupta N, Fan G, Gelinas C. Regulation of programmed cell death by NF-κB and its role in tumorigenesis and therapy. Adv Exp Med Biol 2008; 615: 223-250.
35. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 1999; 13: 2658-2669.
36. Sasaki S, Ito E, Toki T, Maekawa T, Kanezaki R, Umenai T et al. Cloning and expression of human B cell-specific transcription factor BACH2 mapped to chromosome 6q15. Oncogene 2000; 19: 3739-3749.
37. Muto A, Tashiro S, Tsuchiya H, Kume A, Kanno M, Ito E et al. Activation of Maf/AP-1 repressor Bach2 by oxidative stress promotes apoptosis and its interaction with promyelocytic leukemia nuclear bodies. J Biol Chem 2002; 277: 20724-20733.
38. Hoshino H, Kobayashi A, Yoshida M, Kudo N, Oyake T, Motohashi H et al. Oxidative stress abolishes leptomycin B-sensitive nuclear export of transcription repressor Bach2 that counteracts activation of Maf recognition element. J Biol Chem 2000; 275: 15370-15376.
39. Swaminathan S, Huang C, Geng H, Chen Z, Harvey R, Kang H et al. BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. Nat Med 2013; 19: 1014-1022.
40. Msaki A, Sanchez AM, Koh LF, Barre B, Rocha S, Perkins ND et al. The role of RelA (p65) threonine 505 phosphorylation in the regulation of cell growth, survival, and migration. Mol Biol Cell 2011; 22: 3032-3040.
41. Zhao B, Barrera LA, Ersing I, Willox B, Schmidt SC, Greenfeld H et al. The NF-κB genomic landscape in lymphoblastoid B cells. Cell Rep 2014; 8: 1595-1606.
42. Grossmann M, Metcalf D, Merryfull J, Beg A, Baltimore D, Gerondakis S. The combined absence of the transcription factors Rel and RelA leads to multiple hemopoietic cell defects. Proc Natl Acad Sci USA 1999; 96: 11848-11853.
43. Pham LV, Tamayo AT, Yoshimura LC, Lin-Lee YC, Ford RJ. Constitutive NF-κB and NFAT activation in aggressive B-cell lymphomas synergistically activates the CD154 gene and maintains lymphoma cell survival. Blood 2005; 106: 3940-3947.
44. Casolari DA, Makri M, Yoshida C, Muto A, Igarashi K, Melo JV. Transcriptional suppression of BACH2 by the Bcr-Abl oncoprotein is mediated by PAX5. Leukemia 2013; 27: 409-415.
45. Ichikawa S, Fukuhara N, Katsushima H, Takahashi T, Yamamoto J, Yokoyama H et al. Association between BACH2 expression and clinical prognosis in diffuse large B-cell lymphoma. Cancer Sci 2014; 105: 437-444.
46. Du P, Kibbe WA, Lin SM. lumi: a pipeline for processing Illumina microarray. Bioinformatics 2008; 24: 1547-1548.
47. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80.
48. Smyth GK. limma: linear models for microarray data. In: Gentleman RC, Carey VJ, Dudoit S, Irizarry R, Huber W (eds). Bioinformatics and Computational Biology Solutions Using R and Bioconductor. Springer: New York, 2005, pp 397-420.
49. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.
50. Greenfeld H, Takasaki K, Walsh MJ, Ersing I, Bernhardt K, Ma Y et al. TRAF1 coordinates polyubiquitin signaling to enhance Epstein-Barr virus LMP1-mediated growth and survival pathway activation. PLoS Pathog 2015; 11: e1004890.
51. Doench JG, Hartenian E, Graham DB, Tothova Z, Hegde M, Smith I et al. Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat Biotechnol 2014; 32: 1262-1267.
52. Naito Y, Hino K, Bono H, Ui-Tei K. CRISPRdirect: software for designing CRISPR/Cas guide RNA with reduced off-target sites. Bioinformatics 2015; 31: 1120-1123.
53. Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods 2014; 11: 783-784.